|
1
|
Ljungberg B, Hanbury DC, Kuczyk MA,
Merseburger AS, Mulders PF, Patard JJ and Sinescu IC; European
Association of Urology Guideline Group for renal cell carcinoma, :
Renal cell carcinoma guideline. Eur Urol. 51:1502–1510. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
White NM, Khella HW, Grigull J, Adzovic S,
Youssef YM, Honey RJ, Stewart R, Pace KT, Bjarnason GA, Jewett MA,
et al: miRNA profiling in metastatic renal cell carcinoma reveals a
tumor-suppressor effect for miR-215. Br J Cancer. 105:1741–1749.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Crispen PL, Breau RH, Allmer C, Lohse CM,
Cheville JC, Leibovich BC and Blute ML: Lymph node dissection at
the time of radical nephrectomy for high-risk clear cell renal cell
carcinoma: Indications and recommendations for surgical templates.
Eur Urol. 59:18–23. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Al-Ali BM, Ress AL, Gerger A and Pichler
M: MicroRNAs in renal cell carcinoma: implications for
pathogenesis, diagnosis, prognosis and therapy. Anticancer Res.
32:3727–3732. 2012.PubMed/NCBI
|
|
5
|
D'Angelo B, Benedetti E, Cimini A and
Giordano A: MicroRNAs: A puzzling tool in cancer diagnostics and
therapy. Anticancer Res. 36:5571–5575. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li M, Wang Y, Song Y, Bu R, Yin B, Fei X,
Guo Q and Wu B: MicroRNAs in renal cell carcinoma: A systematic
review of clinical implications (Review). Oncol Rep. 33:1571–1578.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu
X, Xiao P, Shi H, Wang R, Chen L, et al: MiR-141 Is a key regulator
of renal cell carcinoma proliferation and metastasis by controlling
EphA2 expression. Clin Cancer Res. 20:2617–2630. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nofech-Mozes R, Khella HW, Scorilas A,
Youssef L, Krylov SN, Lianidou E, Sidiropoulos KG, Gabril M, Evans
A and Yousef GM: MicroRNA-194 is a marker for good prognosis in
clear cell renal cell carcinoma. Cancer Med. 5:656–664. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S,
Guo X, Wang B, Gang Y, Zhang Y, et al: mIr-218 inhibits invasion
and metastasis of gastric cancer by targeting the Robo1 receptor.
PLos Genet. 6:e10008792010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu H, Gao G, Jiang L, Guo L, Lin M, Jiao
X, Jia W and Huang J: Decreased expression of miR-218 is associated
with poor prognosis in patients with colorectal cancer. Int J Clin
Exp Pathol. 6:2904–2911. 2013.PubMed/NCBI
|
|
12
|
Liu B, Tian Y, Li F, Zhao Z, Jiang X, Zhai
C, Han X and Zhang L: Tumor-suppressing roles of miR-214 and
miR-218 in breast cancer. Oncol Rep. 35:3178–3184. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi ZM, Wang L, Shen H, Jiang CF, Ge X, Li
DM, Wen YY, Sun HR, Pan MH, Li W, et al: Downregulation of miR-218
contributes to epithelial mesenchymal transition and tumor
metastasis in lung cancer by targeting Slug/ZEB2 signaling.
Oncogene. 36:2577–2588. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li N, Wang LF, Tan GY, Guo ZH, Liu L, Yang
M and He J: MicroRNA-218 inhibits proliferation and invasion in
ovarian cancer by targeting Runx2. Oncotarget. 8:91530–91541.
2017.PubMed/NCBI
|
|
15
|
Yang Y, Ding L, Hu Q, Xia J, Sun J, Wang
X, Xiong H, Gurbani D, Li L, Liu Y and Liu A: MicroRNA-218
functions as a tumor suppressor in lung cancer by targeting
IL-6/STAT3 and negatively correlates with poor prognosis. Mol
Cancer. 16:1412017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu N, Zhang T, Zhao D, Cao Z, Du J and
Zhang Q: CIP2A is overexpressed in human endometrioid
adenocarcinoma and regulates cell proliferation, invasion and
apoptosis. Pathol Res Pract. 214:233–239. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
International Agency for Research on
Cancer. Tumours of the kidney. In: Pathology and Genetics: Tumors
of the Urinary System and Male Genital Organs. Moch H, Humphrey PA,
Ulbright T and Reuter VE: 4th. WHO Classification of Tumors. IARC
Press Zurich; Switzerland: pp. pp7–10. 2015
|
|
19
|
De Meerleer G, Khoo V, Escudier B, Joniau
S, Bossi A, Ost P, Briganti A, Fonteyne V, Van Vulpen M, Lumen N,
et al: Radiotherapy for renal-cell carcinoma. Lancet Oncol.
15:e170–e177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang QB, Ma X, Zhang X, Liu SW, Ai Q, Shi
TP, Zhang Y, Gao Y, Fan Y, Ni D, et al: Down-Regulated miR-30a in
clear cell renal cell carcinoma correlated with tumor hematogenous
metastasis by targeting angiogenesis-Specific DLL4. PLoS One.
8:e672942013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Esquela-Kerscher A and Slack FJ: Oncomirs-
microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ran LJ, Liang J, Deng X and Wu JY: miRNAs
in Prediction of Prognosis in Clear Cell Renal Cell Carcinoma.
Biomed Res Int. 2017:48329312017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
